Eluminex Biosciences Exclusively Licenses FibroGen s Biosynthetic Cornea Technology and Recombinant Collagen III Platform forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
DiaMedica Therapeutics Inc (DMAC) Appoints Amy Burroughs and Charles Semba to its Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
MINNEAPOLIS (BUSINESS WIRE) Jul 15, 2021
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the election of two industry veterans to the Companyâs Board of Directors. Amy Burroughs, President and CEO of Cleave Therapeutics, brings over 20 years of experience in business and commercial development, strategy and leadership in the pharmaceutical industry. Dr. Charles Semba, Chief Medical Officer of Eluminex Biosciences, has over 20 years of drug-development experience in high growth public and private therapeutics companies and serves on the faculty of Vascular/Interventional Radiology at Stanford University.